Journey Medical Corporation announced that the FDA has accepted the Company's New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 USD | -2.86% | -2.30% | -40.97% |
Mar. 21 | Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024 | |
Mar. 21 | Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.97% | 67.77M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- DERM Stock
- News Journey Medical Corporation
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea